{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:47Z","timestamp":1787027027932,"version":"build-2736575974"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background and aims:<\/jats:title>\n                    <jats:p>High-dose Obeticholic acid exhibits promise for non-alcoholic fatty liver disease (NAFLD) treatment but can induce lipotoxicity. Our study sought to understand this mechanism and propose a solution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Approach and Results:<\/jats:title>\n                    <jats:p>\n                      In a non-alcoholic fatty liver disease (NAFLD) model induced by a high-fat diet in FXR\n                      <jats:sup>\u2212\/\u2212<\/jats:sup>\n                      mice, we pinpointed that FXR regulated the expression of ACOX1 through RNA-Seq analysis. In the livers of FXR\n                      <jats:sup>\u2212\/\u2212<\/jats:sup>\n                      mice, both ACOX1 mRNA and protein expression notably decreased. In both HL-7702 and HEP-G2 cells, the silencing of FXR through shRNA plasmids decreased ACOX1 expression, while FXR activation with GW4064 increased it. These effects were reversible with the ACOX1-specific inhibitor, 10,12-Tricosadiynoic acid. In the NAFLD model of FXR\n                      <jats:sup>\u2212\/\u2212<\/jats:sup>\n                      mice, The activation of ACOX1 is correlated with elevated serum LDL, triglycerides, and aggravated hepatic steatosis. However, the combination of 10,12-Tricosadiynoic acid with low-dose obeticholic acid effectively treated hepatic steatosis, reducing LDL levels in the NAFLD model of wild-type mice. This combination therapy demonstrated efficacy comparable to high-dose obeticholic acid alone. Notably, the combined drug regimen treats hepatic steatosis by inhibiting the IL-1\u03b2 and \u03b1-SMA pathways in NAFLD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Combining ACOX1-specific inhibitors with low-dose obeticholic acid effectively treats high-fat diet-induced hepatic steatosis and reduces serum LDL. This approach enhances the therapeutic effects of obeticholic acid and mitigates its lipotoxicity by inhibiting the IL-1\u03b2 and \u03b1-SMA pathways.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2024.1366479","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T09:51:53Z","timestamp":1711446713000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Inhibition of ACOX1 enhances the therapeutic efficacy of obeticholic acid in treating non-alcoholic fatty liver disease and mitigates its lipotoxicity"],"prefix":"10.3389","volume":"15","author":[{"given":"Yuping","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weinan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuangzhen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenshen","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqi","family":"Kou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"114089","DOI":"10.1016\/j.ejmech.2021.114089","article-title":"Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis","volume":"230","author":"Cao","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"B2","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s11883-015-0500-2","article-title":"FXR agonists as therapeutic agents for non-alcoholic fatty liver disease","volume":"17","author":"Carr","year":"2015","journal-title":"Curr. Atheroscler. Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/bmb\/ldaa006","article-title":"Obeticholic acid-a new therapy in PBC and NASH","volume":"133","author":"Chapman","year":"2020","journal-title":"Br. Med. Bull."},{"key":"B4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.freeradbiomed.2021.04.018","article-title":"PPAR\u03b1 agonist WY-14,643 enhances ethanol metabolism in mice: role of catalase","volume":"169","author":"Chen","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/s42255-021-00489-2","article-title":"Peroxisomal \u03b2-oxidation acts as a sensor for intracellular fatty acids and regulates lipolysis","volume":"3","author":"Ding","year":"2021","journal-title":"Nat. Metab."},{"key":"B6","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41423-018-0032-0","article-title":"Increased Tim-3 expression alleviates liver injury by regulating macrophage activation in MCD-induced NASH mice","volume":"16","author":"Du","year":"2019","journal-title":"Cell. Mol. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1152\/physrev.00013.2007","article-title":"Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver","volume":"88","author":"Friedman","year":"2008","journal-title":"Physiol. Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nrrheum.2010.4","article-title":"IL-1 pathways in inflammation and human diseases","volume":"6","author":"Gabay","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.omtn.2019.10.045","article-title":"Therapeutic potential of LNP-mediated delivery of miR-634 for cancer therapy","volume":"19","author":"Gokita","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.molcel.2020.05.007","article-title":"Acetyl-CoA derived from hepatic peroxisomal \u03b2-oxidation inhibits autophagy and promotes steatosis via mTORC1 activation","volume":"79","author":"He","year":"","journal-title":"Mol. Cell"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1080\/15548627.2020.1797288","article-title":"Hepatic peroxisomal \u03b2-oxidation suppresses lipophagy via RPTOR acetylation and MTOR activation","volume":"16","author":"He","year":"","journal-title":"Autophagy"},{"key":"B13","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3181\/0707-MR-190","article-title":"Mechanisms of fibrogenesis","volume":"233","author":"Kisseleva","year":"2008","journal-title":"Exp. Biol. Med. (Maywood, N.J.)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatol. Baltim. Md."},{"key":"B16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1042\/BJ20041896","article-title":"A role for PPARalpha in the control of SREBP activity and lipid synthesis in the liver","volume":"389","author":"Knight","year":"2005","journal-title":"Biochem. J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"880508","DOI":"10.3389\/fphar.2022.880508","article-title":"Obeticholic acid induces hepatoxicity via FXR in the NAFLD mice","volume":"13","author":"Lin","year":"","journal-title":"Front. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"112984","DOI":"10.1016\/j.biopha.2022.112984","article-title":"Obeticholic acid inhibits hepatic fatty acid uptake independent of FXR in mouse","volume":"150","author":"Lin","year":"","journal-title":"Biomed. Pharmacother. = Biomedecine Pharmacother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1385\/cbb:32:1-3:73","article-title":"Peroxisomal lipid degradation via beta- and alpha-oxidation in mammals","volume":"32","author":"Mannaerts","year":"2000","journal-title":"Cell Biochem. biophysics"},{"key":"B20","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet London, Engl."},{"key":"B21","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatol. Baltim. Md"},{"key":"B23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/joim.13531","article-title":"Current treatment of non-alcoholic fatty liver disease","volume":"292","author":"Paternostro","year":"2022","journal-title":"J. Intern. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","author":"Quek","year":"2023","journal-title":"lancet. Gastroenterology hepatology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1016\/j.ajpath.2019.07.019","article-title":"Smooth muscle \u03b1-actin deficiency leads to decreased liver fibrosis via impaired cytoskeletal signaling in hepatic stellate cells","volume":"189","author":"Rockey","year":"2019","journal-title":"Am. J. pathology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2019.10.006","article-title":"Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis","volume":"72","author":"Siddiqui","year":"2020","journal-title":"J. hepatology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.jhep.2015.03.039","article-title":"Mechanisms of liver fibrosis resolution","volume":"63","author":"Tacke","year":"2015","journal-title":"J. hepatology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatol. Baltim. Md."},{"key":"B29","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat. Rev. Gastroenterology hepatology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1186\/s13063-021-05719-2","article-title":"IL-1 Signal Inhibition in Alcoholic Hepatitis (ISAIAH): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis","volume":"22","author":"Vergis","year":"2021","journal-title":"Trials"},{"key":"B31","doi-asserted-by":"publisher","first-page":"109609","DOI":"10.1016\/j.biopha.2019.109609","article-title":"Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease","volume":"121","author":"Xi","year":"2020","journal-title":"Biomedecine Pharmacother."},{"key":"B32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bbrc.2022.04.132","article-title":"PPAR\u03b1 agonist WY-14,643 induces the PLA2\/COX-2\/ACOX1 pathway to enhance peroxisomal lipid metabolism and ameliorate alcoholic fatty liver in mice","volume":"613","author":"Xu","year":"2022","journal-title":"Biochem. biophysical Res. Commun."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatol. Baltim. Md."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet London, Engl."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1074\/jbc.M116.763532","article-title":"Specific inhibition of acyl-CoA oxidase-1 by an acetylenic acid improves hepatic lipid and reactive oxygen species (ROS) metabolism in rats fed a high fat diet","volume":"292","author":"Zeng","year":"2017","journal-title":"J. Biol. Chem."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1366479\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T09:51:56Z","timestamp":1711446716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1366479\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":35,"alternative-id":["10.3389\/fphar.2024.1366479"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1366479","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,26]]},"article-number":"1366479"}}